Comparing the current results to its competitors, Cel Sci reported Revenue decrease in the 4 quarter 2024 year on year by 0 %, despite the revenue increase by the most of its competitors of 9.93 %, recorded in the same quarter.
Cel sci Corporation, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 16.61 %
Cardiff Oncology Inc. is a biomedical company that follows a business model focused on developing and commercializing transformative therapies for the treatment of cancer. They leverage cutting-edge research and technologies to discover novel drug candidates and conduct pre-clinical and clinical trials to evaluate their efficacy. Through strategic partnerships and collaborations, they aim to bring their innovative oncology treatments to market, addressing unmet medical needs and improving patient outcomes.
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Immunogen Inc is a biotechnology company that focuses on the development of antibody-drug conjugates (ADCs) for the treatment of various types of cancer. Their business model is centered around leveraging their proprietary technology platform to create ADCs that deliver potent cancer-killing agents directly to tumor cells. By partnering with pharmaceutical companies, Immunogen aims to advance their ADC candidates through clinical trials and ultimately bring them to market, aiming to improve the lives of cancer patients.
Incyte Corporation is a biopharmaceutical company that primarily focuses on the research, development, and commercialization of innovative medicines targeting oncology and serious inflammatory conditions. Their business model emphasizes robust R&D investments to discover potential drug candidates, often engaging in collaborations with other organizations to enhance their development capabilities. Incyte leverages its extensive intellectual property portfolio to protect and maximize the value of its therapeutic advancements in the market.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Revolution Medicines Inc operates as a biopharmaceutical company that focuses on discovering and developing new drugs to target cancers and other diseases caused by defects in cellular signaling. Their business model involves leveraging their expertise in precision oncology and molecular biology to identify novel drug candidates and advance them through preclinical and clinical development stages.
Seagen Inc is a biotechnology company that focuses on developing and commercializing innovative cancer therapeutics. Their business model revolves around research and development of targeted antibody-based drugs, specifically using their proprietary antibody-drug conjugate (ADC) technology. Seagen Inc also seeks strategic collaborations and partnerships with other pharmaceutical companies to enhance their product pipeline and expand their market reach.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
